glp-1 and dual glp-1/gip receptor agonists Agonist | Tirzepatide | Obesity & T2DM Mx | Harrison's Update(22nd Ed.) The Road towards Triple Agonists:

Description

initiated a Phase 3 clinical trial for its investigational GLP-1 agonist compound MariTide, targeting obesity and cardiometabolic comorbidities

McCarty D, Coleman M, Boland CL

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape

Multiple linear regression was used to estimate the average changes of the biomarkers

Cardiovascular Risk Reduction When you combine significant weight loss, improved blood pressure, better lipid profiles, reduced inflammation, and improved glycemic control, the composite cardiovascular risk profile improves substantially